Current guidelines from Europe6 and the United States7 recommend initiating GLP-1RAs therapy promptly after the failure of oral hypoglycemic agents, prioritizing their use over insulin therapy
A physician who has seen the same patient for three years knows their GI history, knows how they responded to previous medication adjustments, and can tell the difference between nausea from a dose increase and nausea from something else entirely
Yet it is Lillys newest drug, tirzepatide, which poses a more serious threat to Novos market dominance
however, the trial only assessed carotid plaque
The coverage for the medication is provided through the Medicare GLP-1 Bridge program and is separate from your Medicare Part D prescription drug benefit
The goal is to enable personalized GLP-1RA therapy that maximizes efficacy, minimizes adverse effects, and improves long-term outcomes in type 2 diabetes and obesity management [129,140]